Stock Price
200.40
Daily Change
-6.61 -3.19%
Monthly
-26.26%
Yearly
66.07%
Q4 Forecast
202.35

EPS Reference Time Actual Consensus Previous
2026-10-29 FY2026Q3 PM 1.44 1.36 1.34
2026-07-30 FY2026Q2 PM 1.31 1.23 1.19
2026-04-30 FY2026Q1 PM 1.15 1.06 0.97
2026-02-05 FY2025Q4 PM 1.35 1.22 0.95
2025-10-30 FY2025Q3 PM 1.34 1.16 1.14



Peers Price Chg Day Year Date
Agilent 173.54 -0.42 -0.24% 20.08% Nov/16
Bio-Rad Laboratories 364.07 -2.29 -0.63% 16.26% Nov/16
Bruker 61.08 -0.51 -0.83% 46.76% Nov/16
Boston Scientific 43.88 -0.46 -1.04% -56.88% Nov/16
Charles River Laboratories 337.16 -0.81 -0.24% 107.18% Nov/16
Quest Diagnostics 262.21 2.61 1.01% 40.83% Nov/16
Danaher 232.06 -0.96 -0.41% 5.27% Nov/16
Edwards Lifesciences 106.84 -0.31 -0.29% 26.08% Nov/16
Standard Biotools 0.64 -0.07 -9.87% -48.58% Nov/16
Illumina 200.40 -6.61 -3.19% 66.07% Nov/16

Indexes Price Day Year Date
USND 24593 -543.76 -2.16% 8.30% Nov/16
US Index 500 7439 -122.88 -1.63% 11.49% Nov/16

Illumina traded at $200.40 this Monday November 16th, decreasing $6.61 or 3.19 percent since the previous trading session. Looking back, over the last four weeks, Illumina lost 26.26 percent. Over the last 12 months, its price rose by 66.07 percent. Looking ahead, we forecast Illumina to be priced at 202.35 by the end of this quarter and at 189.00 in one year, according to Trading Economics global macro models projections and analysts expectations.

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.